Download PDF
Exp Clin Endocrinol Diabetes 1991; 97(1): 113-116
DOI: 10.1055/s-0029-1211050
Short Communication

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Failure of Anti-TSH Receptor Antibodies (TRAb) to Predict the Outcome of the Course of Graves' Disease Following Withdrawal of Antithyroid Drug

Y. Shoda, H. Akiyama, T. Yamaguchi, T. Inukai1 , I. Kobayashi2 , Y. Kondo3 , S. Kobayashi1
  • School of Medicine, Gunma University, Maebashi/Japan
  • 1First Department of Internal Medicine, Gunma University, Maebashi/Japan
  • 2Clinical Laboratory Center, Gunma University, Maebashi/Japan
  • 3Department of Physical Biochemistry, Institute of Endocrinology, Gunma University, Maebashi/Japan
Further Information

Publication History

1990

Publication Date:
16 July 2009 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Nineteen patients with Graves' disease were regarded as euthyroid at the end of therapy. Follow-up studies were performed for further 3 years. TSH bindung inhibitor immuno-globins (TBII) were measured by radioreceptor assay. Thyroid stimulating antibodies (TSAb) were measured by a sensitive cAMP accumulation using FRTL-5 cells. Most of the patients showed negative TBII at the end of therapy, while TSAb-positive patients were approximately 50%. The relapse rates during post therapeutic period were 33.3% in TSAb-positive group and 40% in TSAb-negative group, which were not significantly different between the two groups. It was thought that determination of TSAb activity at the end of therapy, in addition to TBII, appears to play a permissive role in predicting the outcome of the course of Graves' disease following discontinuation of anti-thyroid drug therapy.

Key words

Anti-TSH receptor antibodies - Graves' disease - Relapse

      >